Immunome (IMNM) Invested Capital (2023 - 2025)
Historic Invested Capital for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $263.9 million.
- Immunome's Invested Capital rose 2280.67% to $263.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $263.9 million, marking a year-over-year increase of 2280.67%. This contributed to the annual value of $181.2 million for FY2024, which is 5111.94% up from last year.
- As of Q3 2025, Immunome's Invested Capital stood at $263.9 million, which was up 2280.67% from $269.3 million recorded in Q2 2025.
- Immunome's 5-year Invested Capital high stood at $307.1 million for Q1 2025, and its period low was $6.1 million during Q3 2023.
- Over the past 3 years, Immunome's median Invested Capital value was $214.9 million (recorded in 2024), while the average stood at $175.0 million.
- Per our database at Business Quant, Immunome's Invested Capital skyrocketed by 343696.51% in 2024 and then surged by 607.95% in 2025.
- Immunome's Invested Capital (Quarter) stood at $119.9 million in 2023, then soared by 51.12% to $181.2 million in 2024, then skyrocketed by 45.68% to $263.9 million in 2025.
- Its Invested Capital was $263.9 million in Q3 2025, compared to $269.3 million in Q2 2025 and $307.1 million in Q1 2025.